Can we skip weekends in GnRH antagonist cycles without compromising the final outcome?

The author discusses the challenges in programming GnRH antagonist cycles.

Like Comment


Ernesto Bosch, M.D.

Vol 97, Issue 6 , Pages 1299-1300


Gonadotropin-releasing hormone (GnRH) antagonists were introduced into clinical practice more than a decade ago. However, although they offer a number of advantages compared with GnRH agonists, their introduction in daily practice has been slower than initially could be expected. A major drawback for their consolidation has been the limitation for programming cycles, as when the GnRH antagonist protocol gonadotropin administration is started on day 2 or 3 of menses, which is clearly an unpredictable event.

Read the full text at:

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.